Features:
It is indicated in the regular treatment of asthma where use of a combination product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate:

Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta-2-agonist

Or patients already adequately controlled on both inhaled corticosteroid and long-acting beta-2-agonist.

25mcg/50mcg/dose, 25mcg/125mcg/dose, 25mcg/250mcg/dose